AI Insight
Researchers have found that newer oral anticoagulants (NOACs) may slow cognitive decline in patients with both Alzheimer's disease and atrial fibrillation. Patients taking NOACs showed slower deterioration in cognitive function compared to those using the older blood thinner warfarin or no anticoagulants at all. While the effect was modest on an annual basis, the researchers suggest the benefits could accumulate over extended periods.
Why it matters
This finding could influence treatment decisions for the significant population of patients who have both Alzheimer's disease and atrial fibrillation, potentially offering a dual benefit of stroke prevention and cognitive protection. If confirmed in larger studies, this could lead to revised clinical guidelines for managing patients with these co-occurring conditions.
Understand the Science
Newer blood thinners may do more than prevent strokes in people with Alzheimer’s disease and atrial fibrillation. Researchers found that patients taking NOACs experienced a slower decline in cognitive function than those using warfarin or no blood thinners. The effect was modest each year but could add up over time.
Source: These blood thinners may have an unexpected benefit for Alzheimer’s patients